SANUWAVE Health, Inc. (NASDAQ:SNWV) shares are trading lower by 5% on Friday. This week, the company reported second-quarter preliminary results.
Details
Sanuwave Health expects second quarter 2026 revenue to range from $9.6 million to $9.8 million, exceeding the high end of its previous guidance of $8.5 million–$9.5 million.
Revenue declined approximately 3%–5% year over year compared with $10.1 million reported in the prior year quarter.
CEO Morgan Frank said second-quarter revenue exceeded the upper end of the company’s June guidance range, with overall performance largely in line with expectations.
Capital sales remained pressured by customer financial constraints and increased availability of used UltraMIST systems.
To address this, Sanuwave has supported new users through qualification, training, and service programs, while offering trade-in options for certified pre-owned systems backed by manufacturer warranties.
The company highlighted strong momentum in consumable applicator sales, which reached record highs in both units sold and revenue.
What Is SANUWAVE Health and Its Business Model
SANUWAVE Health is a medical device company selling directed energy products into wound care, focused on commercializing patented regenerative medicine that uses noninvasive ultrasound or shockwaves to trigger a biological response that supports tissue repair and regeneration.
Its FDA-cleared, commercialized product is the UltraMIST system, used to treat a range of acute and chronic wounds using ultrasound technology.
The company operates in a single reportable segment (design and sale of medical devices) and generates most of its revenue in the United States. That’s why the preliminary Q2 revenue range matters: for a single-product-focused med-tech story, sales traction is often the clearest near-term read on adoption, even if the chart is still signaling a longer-term downtrend.
SANUWAVE Health’s Benzinga Edge Scorecard Explained
Below is the Benzinga Edge scorecard for SANUWAVE Health, highlighting its strengths and weaknesses compared to the broader market:
- Momentum: Weak (Score: 0.61) — The stock is showing extremely weak trend strength versus the broader market, which lines up with its position below key moving averages.
- Value: Neutral (Score: 46.16) — The valuation profile looks more middle-of-the-road on this framework. Hence, price action is likely being driven more by trend and execution than “cheap vs. expensive” alone.
- Growth: Strong (Score: 99.28) — The model is flagging strong growth characteristics, which fits with the market focusing on revenue updates like the $9.6 million to $9.8 million preliminary Q2 range.
The Verdict: SANUWAVE Health’s Benzinga Edge signal reveals a growth-tilted profile that’s being overshadowed by very weak momentum. For longer-term bulls, the setup improves if revenue strength starts to translate into sustained trend reversals on the chart, starting with reclaiming the 20-day and 50-day moving averages.
SNWV Price Action: Sanuwave shares are trading down 4.44% at $6.36 at the time of publication on Friday, according to Benzinga Pro data.
Photo via Shutterstock
